Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 276 to 300 of 2013

TitleReference numberPublishedLast updated
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessmentHTG713
Ovarian cancer: identifying and managing familial and genetic riskNG241
Momelotinib for treating myelofibrosis-related splenomegaly or symptomsTA957
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and managementNG240
Neonatal infection: antibiotics for prevention and treatmentNG195
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessmentHTG664
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Lung cancer: diagnosis and managementNG122
Vitamin B12 deficiency in over 16s: diagnosis and managementNG239
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Digital technologies for delivering multidisciplinary weight-management services: early value assessmentHTG700
Digital technologies for managing non-specific low back pain: early value assessmentHTG712
Endoscopic sleeve gastroplasty for obesityHTG711
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
TuberculosisNG33
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947

Results per page

  1. 10
  2. 25
  3. 50
  4. All